Designated Breakthrough Therapies Draw Support from Calyx

Calyx CEO Gavin Nichols discusses the significance of the FDA’s Breakthrough Therapy designation.

Outsourcing-Pharma recently spoke with Calyx CEO Gavin Nichols about the significance of the FDA’s Breakthrough Therapy designation, Calyx’s role in helping to bring half of the recently approved breakthrough oncology treatments to market, and what it might mean for pharma firms, development partners, and other key stakeholders.

You can read the full article at the link below:

Designated Breakthrough Therapies Draw Support from Calyx